Newcells Biotech are a fast-growing team of global scientific and industry experts based in state of the art facilities in the Helix Science Campus of Newcastle-upon-Tyne in the UK. Our purpose is to bridge the gap between scientific discovery and patients and we make a difference by providing better predictions of clinical outcomes. Using our expertise in induced pluripotent stem cells (iPSCs), cellular physiology and organoid technology, we build functional pre-clinical in vitro models of retina, kidney, liver and lung.
MIMETAS enables scientists to develop better predictive human tissue and disease models with organ-on-a-chip technology. Our vision is to create the simplest device for the most complex 3D biology. The OrganoPlate® platform allows perfused 3D cell culture, membrane free co-culture and culture of tubules and vessels in a throughput never seen before.
Curi Bio provides a seamless, bioengineered integration of human stem cells, systems, and data to accelerate the discovery of new medicines. Curi’s suite of human stem cell-based products and services enable scientists to build mature and predictive human iPSC-derived tissues—with a focus on cardiac, skeletal muscle, and neuromuscular models—for the discovery, safety testing, and efficacy testing of new therapeutics. Curi seeks to de-risk and expedite the development of new drugs by decreasing the industry’s dependence on animal models, which often fail to translate to humans. By providing researchers human-relevant preclinical data at the earliest stages of the development pipeline, Curi aims to dramatically accelerate the discovery and development of safer, more effective medicines.
Obatala Sciences, Inc is a biotechnology company that offers brain power and research tools to advance the fields of obesity, diabetes, related metabolic disorders and cancers, and regenerative medicine. Our mission is to drive diversity in research and impact the future of regenerative medicine. To advance this mission, we manufacture adult stem/stromal cells, unique 3D cell culture tools, and we are progressing an FDA-approved protocol for testing a stem cell based therapy for wound healing applications in humans.
StemoniX, a Vyant Bio company, brings a human-first approach to drug discovery, simplifying and accelerating biomarker-based compound discovery to treat complex diseases. Using proprietary high-throughput, human iPSC-derived 2D and 3D neural platforms and advanced data analytics, StemoniX creates predictive, accurate, and consistent human microOrgan models that enable scientists to identify clinically relevant biomarkers to drive the discovery of new targets and hits in a simplified workflow. StemoniX partners with biopharma to identify and validate new compounds, create new cell-based disease models, and operationalize custom human iPSC disease models for high-throughput discovery. Together with the combined preclinical and regulatory expertise of their sister company, vivoPharm, StemoniX is helping global institutions bring the most promising medicines to patients. StemoniX.com
Hubrecht Organoid Technology (HUB)
Hubrecht Organoid Technology (HUB) was founded by the Hubrecht Institute, the University Medical Center Utrecht, and the Royal Netherlands Academy of Arts and Sciences (KNAW) to refine organoid development and foster organoid adoption globally. HUB Organoid Technology represents a paradigm-shift that bridges the gap between the lab and the clinic and effectively brings “patients in the lab” for drug discovery and development, preclinical patient stratification, predictive biomarker discovery, personalized medicine, clinical trials, regenerative medicine, and companion diagnostics applications.